Aethlon Medical Inc.
AEMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AEMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AEMD
Aethlon Medical Inc. is a clinical-stage therapeutic device company developing the Hemopurifier for cancer and infectious diseases, with a recent oncology trial showing no device-related serious adverse events and ongoing financial challenges.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aethlon Medical Inc..
Aethlon Medical Inc. is a clinical-stage therapeutic device company developing the Hemopurifier for cancer and infectious diseases, with a recent oncology trial showing no device-related serious adverse events and ongoing financial challenges.
- Completed first cohort of three patients in an oncology trial in Australia with no device-related serious adverse events and no dose-limiting toxicities [sec · filed 2026-01-16].
- Cash and cash equivalents were approximately $5 million as of March 31, 2026 [sec · filed 2026-06-22], and $5.0M as of June 30, 2026 per latest reported financials [sec].
- Net loss for the three months ended June 30, 2026 was $1,547,912, improved from $1,761,858 in the same period of 2025 [sec_mda · as of 2026-08-13].
- Nasdaq compliance matters that arose in 2025 have been resolved, and the company remains listed on the Nasdaq Capital Market [sec · filed 2026-01-16].
- The company has incurred recurring losses and expects to require additional capital to fund operations beyond the next twelve months [sec_mda · as of 2026-08-13].
What works
- First cohort of three patients in the oncology trial in Australia completed without device-related serious adverse events or dose-limiting toxicities, indicating initial safety [sec · filed 2026-01-16].
- Expense reductions have contributed to a decreased net loss year-over-year, from $1,761,858 to $1,547,912 for the three months ended June 30 [sec_mda · as of 2026-08-13].
- Cash and cash equivalents as of June 30, 2026, together with subsequent proceeds, are believed sufficient to fund planned operations for at least twelve months [sec_mda · as of 2026-08-13].
What to weigh
- Substantial doubt exists that cash on hand will carry the company for 12 months beyond the filing date of the Annual Report for the period ended March 31, 2026 [sec · filed 2026-06-22].
- The company has incurred recurring losses and negative cash flows from operations, expecting these conditions to continue [sec_mda · as of 2026-06-10].
- Additional capital is required to continue advancing clinical development beyond the current twelve-month runway, with no assurance of availability on acceptable terms [sec_mda · as of 2026-08-13].
- The company may never successfully commercialize the Hemopurifier or become profitable [sec · filed 2026-06-22].
From the filings
Quoted directly from source documents.
First cohort of oncology trial completed with no device-related serious adverse events
“We have now completed the first cohort of three patients in our oncology trial in Australia treated without device-related serious adverse events and no dose-limiting toxicities observed”
SEC filings · January 16, 2026
Cash position as of March 31, 2026
“we had approximately $5 million in cash and cash equivalents as of March 31, 2026”
SEC filings · June 22, 2026
Net loss decreased in Q1 FY2027
“our net loss decreased to $1,547,912 in the three months ended June 30, 2026 from $1,761,858 in the three months ended June 30, 2025”
SEC MD&A · August 13, 2026
Nasdaq compliance resolved
“Nasdaq compliance matters that arose in 2025 have been resolved, and the company remains listed on the Nasdaq Capital Market”
SEC filings · January 16, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Substantial doubt that cash will last 12 months beyond the Annual Report filing date [sec · filed 2026-06-22]
- Need for additional capital — Requires additional capital to continue clinical development beyond current runway; no assurance of financing [sec_mda · as of 2026-08-13]
- Commercialization risk — May never successfully commercialize the Hemopurifier or become profitable [sec · filed 2026-06-22]
- Recurring losses — Incurred recurring losses and negative cash flows, expected to continue for the foreseeable future [sec_mda · as of 2026-06-10]
What to watch
- Progress and results of the ongoing oncology trial in Australia, including subsequent cohorts [sec · filed 2026-01-16]
- Ability to raise additional capital through equity offerings, debt financings, or strategic transactions [sec_mda · as of 2026-08-13]
- Expense reduction initiatives and their impact on cash runway and net loss [sec · filed 2026-06-22]
- Any updates on Hemopurifier development for infectious disease indications [sec · filed 2026-01-16]
Sources: SEC filings · SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run Aethlon Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aethlon Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
8.2 months
D/E 0.20 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$87K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 24,364 | $53K |
| xtx topco ltd | 13,342 | $29K |
| morgan stanley | 2,047 | $4K |
| group one trading llc | 14 | $31 |
| blackrock, inc. | 10 | $22 |
| wells fargo & company/mn | 3 | $6 |
| danske bank a/s | 1 | $2 |
Short Interest
as of May 12, 2026- % of float
- 0.9%
- Days to cover
- 1.1
- Shares short
- 14,050
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AEMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aethlon Medical Inc.?
Aethlon Medical Inc. is a clinical-stage therapeutic device company developing the Hemopurifier for cancer and infectious diseases, with a recent oncology trial showing no device-related serious adverse events and ongoing financial challenges.
What is Aethlon Medical Inc.'s lead drug candidate?
Aethlon Medical Inc.'s most advanced tracked candidate is hemopurifier (Phase 1) for Solid tumors in patients with stable or progressive disease during anti-PD-1 monotherapy.
Who is the CEO of Aethlon Medical Inc.?
Mr. James B. Frakes M.B.A. is the chief executive officer of Aethlon Medical Inc. (AEMD).
Where is Aethlon Medical Inc. headquartered?
Aethlon Medical Inc. (AEMD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Aethlon Medical Inc. focus on?
Aethlon Medical Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.